We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Beckman to Take Over Sales of Access System

By HospiMedica staff writers
Posted on 25 Sep 2000
The sales of the Access immunoassay instrument system and test kits in 90 markets in Europe, Africa, and the Pacific Rim will be taken over by owner Beckman Coulter (Fullerton, CA, USA), the company has announced. Beckman decided not to renew its distribution contract for Access with Bio-Rad Laboratories. The Access business was purchased by Beckman Coulter in 1997 from Pasteur Sanofi Diagnostics (PSD), which became the distributor of the product at that time. Later, Bio-Rad acquired Sanofi and took over the distribution.

In order for Beckman Coulter to leverage our strength in total laboratory workflow and to optimize the value it creates for our customers, our conversations with Bio-Rad have led to the conclusion that it is in the best interest of both companies not to renew the agreement, said John P. Wareham, chairman, president, and CEO of Beckman Coulter.

The Access system is a random-access benchtop analyzer that performs a variety of assays, including test panels for cancer, anemia, cardiac problems, and infectious diseases. Separate research and development partnerships and contract manufacturing agreements are not affected by this decision and will be continued, said Beckman Coulter.

Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
Automated Clinical Chemistry Analyzer
Envoy 500+

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
25 Sep 2000  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
25 Sep 2000  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
25 Sep 2000  |   Industry



PURITAN MEDICAL